Cargando…

Endothelial dysfunction and its critical role in COVID‐19‐associated coagulopathy: Defibrotide as an endothelium‐protective, targeted therapy

Detalles Bibliográficos
Autores principales:	García‐Bernal, David, Richardson, Edward, Vlodavsky, Israel, Carlo‐Stella, Carmelo, Iacobelli, Massimo, Jara, Rubén, Richardson, Paul G., Moraleda, Jose M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426874/ https://www.ncbi.nlm.nih.gov/pubmed/34518829 http://dx.doi.org/10.1002/jha2.198

Ejemplares similares

Response to Maccio et al, “Multifactorial pathogenesis of COVID‐19‐related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?”
por: Richardson, Edward, et al.
Publicado: (2020)

Defibrotide for the Treatment of Endotheliitis Complicating Sars-Cov-2 Infection: Rationale and Ongoing Studies As Part of the International Defacovid Study Group
por: Moraleda, Jose M., et al.
Publicado: (2020)

Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide
por: Shi, Hui, et al.
Publicado: (2021)

Use of Defibrotide in Patients with COVID-19 Pneumonia; Results of the Defi-VID19 Phase 2 Trial
por: Ruggeri, Annalisa, et al.
Publicado: (2021)

The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae
por: Richardson, Paul G., et al.
Publicado: (2021)

Defibrotide inhibits donor leucocyte‐endothelial interactions and protects against acute graft‐versus‐host disease
por: García‐Bernal, David, et al.
Publicado: (2020)

Up‐regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide
por: Palomo, Marta, et al.
Publicado: (2019)

A Meta-Analysis Evaluating the Incidence of Bleeding Events With Intravenous Defibrotide Treatment Outside the Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Setting
por: Tappe, William, et al.
Publicado: (2020)

Final results from a defibrotide treatment‐IND study for patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome
por: Kernan, Nancy A., et al.
Publicado: (2018)

Defibrotide Therapy for SARS-CoV-2 ARDS
por: Frame, David, et al.
Publicado: (2022)

Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome
por: Yanik, Gregory A, et al.
Publicado: (2021)

Defibrotide for hepatic veno-occlusive disease
Publicado: (2021)

Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
por: Richardson, Paul, et al.
Publicado: (2019)

Acute Graft-vs.-Host Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide
por: Martinez-Sanchez, Julia, et al.
Publicado: (2019)

Pre-Exposure to Defibrotide Prevents Endothelial Cell Activation by Lipopolysaccharide: An Ingenuity Pathway Analysis
por: Orlando, Nicoletta, et al.
Publicado: (2020)

Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment
por: Richardson, Paul G., et al.
Publicado: (2020)

Pharmacokinetic profile of defibrotide in patients with renal impairment
por: Tocchetti, Paola, et al.
Publicado: (2016)

Defibrotide in the treatment of hepatic veno-occlusive disease
por: Fulgenzi, Alessandro, et al.
Publicado: (2016)

Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
por: Richardson, Paul, et al.
Publicado: (2019)

Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies
por: Elhadad, Sonia, et al.
Publicado: (2023)

Defibrotide Has a Role in COVID-19 Therapy
por: Macciò, Antonio, et al.
Publicado: (2022)

Transfer of Intracellular HIV Nef to Endothelium Causes Endothelial Dysfunction
por: Wang, Ting, et al.
Publicado: (2014)

Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant
por: Nauffal, Mary, et al.
Publicado: (2022)

Coagulopathy is Initiated with Endothelial Dysfunction and Disrupted Fibrinolysis in Patients with COVID-19 Disease
por: Belen Apak, Fatma Burcu, et al.
Publicado: (2023)

Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients
por: Corbacioglu, Selim, et al.
Publicado: (2020)

Endothelial Dysfunction Is Associated with Mortality and Severity of Coagulopathy in Patients with Sepsis and Disseminated Intravascular Coagulation
por: Walborn, Amanda, et al.
Publicado: (2019)

Impact of activated monocyte and endothelial dysfunction on coagulopathy in Egyptian adult beta thalassemic patients
por: Abd El-samee, Hanaa, et al.
Publicado: (2020)

Analysis of Time to Complete Response after Defibrotide Initiation in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation
por: Richardson, Paul G., et al.
Publicado: (2020)

Endothelial cells orchestrate COVID-19 coagulopathy
por: O'Sullivan, Jamie M, et al.
Publicado: (2020)

Validation of the relationship between coagulopathy and localization of hydroxyethyl starch on the vascular endothelium in a rat hemodilution model
por: Azumaguchi, Ryu, et al.
Publicado: (2021)

Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide
por: Kong, Seom Gim, et al.
Publicado: (2022)

Defibrotide improved the outcome of monocrotaline induced rat hepatic sinusoidal obstruction syndrome
por: Liu, Zhenli, et al.
Publicado: (2022)

Pathomechanism and Management of Stroke in COVID-19: Review of Immunopathogenesis, Coagulopathy, Endothelial Dysfunction, and Downregulation of ACE2
por: Rahmawati, Putu Lohita, et al.
Publicado: (2021)

Endothelial Cell Dysfunction and the Vascular Complications Associated with Type 2 Diabetes: Assessing the Health of the Endothelium
por: Ding, Hong, et al.
Publicado: (2005)

Endothelium-specific deletion of amyloid-β precursor protein exacerbates endothelial dysfunction induced by aging
por: d’Uscio, Livius V., et al.
Publicado: (2021)

Light at the ENDothelium-role of Sox17 and Runx1 in endothelial dysfunction and pulmonary arterial hypertension
por: Simmons Beck, Robert, et al.
Publicado: (2023)

Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19
por: Wang, Xin, et al.
Publicado: (2020)

Pooled analysis of Day 100 survival for defibrotide‐treated patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation
por: Richardson, Paul G., et al.
Publicado: (2020)

Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation
por: Giglio, Fabio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_or7l8r42s28t7klf322sngcfdr